I’ve been on chemo (cabazitaxel + carboplatin) since Jan 2022 and also on Zometa and Lupron. PSA went from 1.3 in Jan 2023 to 11.7 this month. CT and Bone scans show bone mets somewhat stable but with activity, all bone no soft tissue. PET PSMA earlier this year did not show enough tracer activity to indicate Lutetium-177 (available at UC Davis, CA with long lead time).
So we are in the process of changing treatment to Radium-223. When asked if I should stay on Xtandi, both my MOs said it’s ok to continue and pretty much left it up to me as there’s no indication it’s affective since PSA is rising.
Any thoughts on staying on Xtandi in which case treatment would be:
Radium-223, Lupron, Xtandi, Zometa.
I appreciate your input,
Blessings to you.